Anoro Ellipta

Anoro Ellipta

umeclidinium + vilanterol




Zuellig Pharma
Concise Prescribing Info
Per inhalation Predispensed umeclidinium 62.5 mcg, vilanterol trifenatate 25 mcg (delivered dose of umeclidinium 55 mcg, vilanterol trifenatate 22 mcg)
Maintenance bronchodilator treatment to relieve symptoms in adult patients w/ COPD.
Dosage/Direction for Use
1 inhalation once daily administered at the same time each day.
Special Precautions
Discontinue use if paradoxical bronchospasm occurs. Not to be used in patients w/ asthma. Not for treatment of acute bronchospasm episodes. COPD deterioration; severe CV disease; urinary retention, narrow-angle glaucoma. Hypokalaemia; transient hyperglycemia. Convulsive disorders or thyrotoxicosis & patients unusually responsive to β2-adrenergic agonists. Monitor plasma glucose in diabetic patients. Concomitant use w/ drugs potentially causing hypokalaemia. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Severe hepatic impairment. Pregnancy & lactation. Ped <18 yr.
Adverse Reactions
UTI, sinusitis, nasopharyngitis, pharyngitis, upper resp tract infection; headache; cough, oropharyngeal pain; constipation, dry mouth.
Drug Interactions
Weakened or antagonised effect by β-adrenergic blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors eg, ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin. Potentiated AR w/ other antimuscarinics & sympathomimetics. Potentiated hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL03 - vilanterol and umeclidinium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Anoro Ellipta inhalation powd 62.5/25 mcg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in